News
Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback